Long-Term Efficacy and Safety Results of CT-P10 and Reference Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma: Phase III Updated Study Results with Median Follow-up of 40 Months
Christian Buske(University Hospital Ulm), Keum Young Ahn(Celltrion (South Korea)), José‐Ángel Hernández‐Rivas(Hospital Universitario Infanta Leonor), Edvard Zhavrid, Larry W. Kwak(The University of Texas MD Anderson Cancer Center), Juan‐Manuel Sancho(Hospital Universitari Germans Trias i Pujol), Gayane Tumyan(Russian Cancer Research Center NN Blokhin), Sung Hyun Kim(Celltrion (South Korea)), Sang Joon Lee(Celltrion (South Korea)), Jin Seok Kim(University of Ulsan), Aliaksandr Prokharau(9th City Clinical Hospital), Wojciech Jurczak(Jagiellonian University), Won-Seog Kim(Samsung Medical Center), Michinori Ogura(Japanese Red Cross Nagoya Daini Hospital), Mariana Vasilică(Institutul Clinic Fundeni), Rajnish Nagarkar(HCG Cancer Centre)
Cited by 3
Related Papers
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
|Journal of Clinical Oncology|2021|630
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2015|604
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|568